Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that data from its brentuximab vedotin (ADCETRIS™) and dacetuzumab (SGN-40) programs will be presented at the 11th International Conference on Malignant Lymphoma (ICML) being held June 15-18, 2011 in Lugano, Switzerland.

Two oral presentations on brentuximab vedotin will feature encore data from the recent American Society of Clinical Oncology (ASCO) Annual Meeting, including updated response and duration of response data from both a pivotal trial in Hodgkin lymphoma and a phase II trial in systemic anaplastic large cell lymphoma (ALCL). An oral presentation on dacetuzumab will provide complete data from a randomized phase IIb clinical trial of dacetuzumab or placebo in combination with Rituxan® (rituximab) plus ifosfamide, carboplatin and etoposide (R-ICE) chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A summary of the company's ICML presentations is below and full abstracts can be accessed in a supplement to the Annals of Oncology, available online at

Brentuximab Vedotin

Durable remissions with SGN-35 (brentuximab vedotin): Updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)

  • Friday, June 17, 2011, 10:50 a.m. Central European Time (CET)
  • Abstract #125
  • Session 11: T-cell lymphoma
  • Presenting author: Dr. Andrei Shustov, University of Washington Medical Center, Seattle, WA

Durable complete remissions in a pivotal phase 2 study of SGN-35 (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma (HL)

  • Saturday, June 18, 2011, 9:15 a.m. CET
  • Abstract #160
  • Session 15: Hodgkin lymphoma
  • Presenting author: Dr. Anas Younes, MD Anderson Cancer Center, Houston, TX


A phase 2b trial comparing dacetuzumab + R-ICE vs placebo + R-ICE in patients with relapsed diffuse large B-cell lymphoma

  • Saturday, June 18, 2011, 8:40 a.m. CET
  • Abstract #140
  • Session: Focus on Monoclonal antibodies
  • Presenting author: Dr. Stephen Ansell, Mayo Clinic, Rochester, MN

Seattle Genetics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New source of stem cells could help treat people with Alagille syndrome